We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing

By LabMedica International staff writers
Posted on 25 Jun 2025

Homologous recombination deficiency (HRD) testing identifies tumors that are unable to effectively repair DNA damage through the homologous recombination repair pathway. More...

This deficiency is often linked to increased genomic instability and serves as a potential biomarker for predicting response to certain cancer therapies.

Although multiple HRD assays are currently available, they differ in their definitions of HRD, the biomarkers they assess, and the algorithms they employ. These variations can impact treatment decisions, especially for patients who may benefit from poly (ADP-ribose) polymerase (PARP) inhibitor therapies. To address this issue, the Association for Molecular Pathology (AMP, Rockville, MD, USA), the premier global molecular diagnostic professional society, has published its best practice recommendations for clinical laboratories developing and performing HRD testing.

To develop these recommendations published in The Journal of Molecular Diagnostics, AMP’s Clinical Practice Committee assembled an expert panel to review current practices and assess the medical literature related to the molecular detection of HRD in clinical settings. The AMP Detection of HRD in Cancer Working Group included organizational representation from the Association of Community Cancer Centers, the American Society of Clinical Oncology, and the College of American Pathologists.

The AMP HRD Working Group developed 12 recommendations focused on the design and validation of HRD assays. These guidelines are based on survey data, a review of more than 4,300 peer-reviewed scientific publications, professional experience, and consensus of the subject matter experts. The recommendations address technical aspects of genomic instability and HRD analysis, including interpretation of genomic scars from tumor and germline next-generation sequencing results and the clinical relevance of HRD biomarkers.

“As part of our assessment, we identified considerable variability in many aspects of HRD testing, including sample requirements, tumor types, molecular methodologies and the biomarkers evaluated,” said Alanna J. Church, M.D., is the chair of AMP’s 2025 Clinical Practice Committee and associate director of the Laboratory for Molecular Pediatric Pathology at Dana-Farber/Boston Children’s Cancer Center. “This new report offers evidence-based recommendations for HRD diagnostic assays to help improve standardization, transparency, quality across laboratories and care for our cancer patients.”

“These recommendations are intended to guide clinical laboratories offering HRD testing and highlight areas where further research and validation are needed,” added Susan Hsiao, M.D., Ph.D., is the chair of the AMP Detection of HRD in Cancer Working Group and associate professor of pathology and cell biology at Columbia University Vagelos College of Physicians and Surgeons. “AMP remains committed to refining these recommendations as scientific knowledge and technology continue to evolve.”

Related Links:
AMP


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.